Reading Time: 3 minutesI have recently updated the clinical trials section of our website with a couple of MND clinical trials that are currently recruiting. This has led me to
Category: Treatments
Reading Time: 3 minutesResults from a phase I clinical trial of a drug known as ISIS 333611 have been published open-access online in the scientific journal Lancet Neurology on
Reading Time: 3 minutesA very much ‘must report on’ session of the 23rd International Symposium on ALS/MND was the clinical trials and trial design session. There are many
Reading Time: 4 minutesA collaborative American research group, led by Prof Aaron Gitler from Stanford University School of Medicine in California, has identified a potential therapeutic target for
Reading Time: 3 minutesPromising results from a Phase II clinical trial for a drug called NP001 have been announced by the biopharmaceutical company Neuraltus. The trial, conducted in America, suggested
Reading Time: 2 minutesSadie’s recent post on the emerging partnership between Peakdale Molecular and the Sheffield Institute for Translational Neuroscience prompted me to say a little about last month’s
Reading Time: 2 minutesThanks to funding and some strategic ‘match-making’ by the MND Association, a new drug may have taken one step closer to beginning clinical trials in
Reading Time: 3 minutes“After a time where patients and sponsors of trials alike had become disheartened about the lack of positive clinical trials, it is exciting to see
Reading Time: 2 minutesIn December last year, we told you about a new drug for uncontrollable laughter and crying (known as the pseudobulbar affect) called Nuedexta that had been approved for
Reading Time: 9 minutesI’m sure many of you who follow our blog have also been following the discussion on our forum about the Neuraltus trial for a drug called NP001.